ATOS vs RCG Comparison

Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.

RENN Fund Inc is a registered, non-diversified, closed-end management investment company. Its investment objective is to provide shareholders with above-market rates of return through capital appreciation and income by a long-term, value oriented investment process that invests in a wide variety of financial instruments, including but not limited to, common stocks, fixed-income securities, including convertible and non-convertible debt securities or loans, distressed debt, warrants, preferred stock, exchange-traded funds and exchange-traded notes, and other instruments. To a lesser extent, the fund sells short stocks, exchange-traded funds, and exchange-traded notes. It invests in various industries, including communication services, surgical and medical instruments, oil and gas, etc.